G · Genpact Limited

Current Thesis

Genpact’s agentic-software pivot depends on technology revenue offsetting its slower services business; the next quarterly report tests that conversion, while a weekly close below $32 ends the recovery thesis. The 2026-08-06 results put Advanced Technology Solutions (ATS) growth at 24.1%, versus 1.9% for Core Business Services. Management’s next-quarter guidance requires ATS growth of at least 25%. Genpact Q2 results.

Since the 2026-09-05 research update, Genpact appointed Sumita Pandit chief financial officer, effective 2026-09-09; Michael Weiner remains an adviser through the first quarter of 2027. This changes financial leadership without establishing a new revenue outcome. September 8 announcement.

As an inference, the narrative is maturing — the 2026-09-01 finance-software launch and September media appearances extend the story, but the latest reported segment results remain those released on 2026-08-06. The market’s 2026-09-18 adjusted close of $34.14 and relative strength index of 29.3 show weak recent price momentum despite that publicity. A subsequent report meeting the technology-growth guidance before the published price invalidation would support the conversion thesis. Genpact release calendar, company newsroom.

Bullish and bearish views on Genpact Limited

The model's bull view on Genpact Limited (G), in brief: Technology growth has reported substance. The bear view: Legacy services dominate reported sales. Both cases follow in full.

Bull Case

• Technology growth has reported substance. ATS generated $363 million in Q2 2026, representing 27% of revenue; Genpact raised its full-year ATS growth outlook to at least 25% on 2026-08-06. These are reported sales and management guidance, respectively. Q2 results.
• Contract value is a management-reported demand measure; the thesis requires its conversion into reported revenue.
• The product offering has expanded. Genpact’s dated release calendar records an Agentic Record-to-Report Suite launch on 2026-09-01. The launch establishes a finance-workflow offering, but the calendar supplies no associated revenue figure. Company release calendar.

Bear Case

• Legacy services dominate reported sales. Core Business Services contributed $980 million, or 73% of Q2 2026 revenue. On 2026-08-06, management guided that segment flat to slightly down for Q3, leaving the faster-growing technology business responsible for the growth argument. Q2 results.
• Cash conversion needs another observation. The Form 10-Q filed on 2026-08-07 reported first-half operating cash flow of $48.9 million against net income of $293.7 million. That period establishes a cash-conversion gap; it does not establish that the gap persists through the year.
• Recent analyst coverage is mixed. Zacks upgraded its rating on 2026-09-07, while an Argus report dated 2026-09-09 lowered its analyst target to $39. These observations are insufficient to establish expanding participation or crowded ownership. Zacks update, Argus report listing.

Setup & Price Structure

The supplied adjusted daily series records a $34.14 close on 2026-09-18, a three-month price increase of 22.1%, and a price 28.5% below its $47.73 trailing-year high. The 14-period relative strength index (RSI) was 29.3. The measured combination is a positive three-month change with weak recent momentum; it does not establish a reversal.

The $32 threshold remains the public research invalidation established in the 2026-09-05 note. It is a defined weekly-close condition, rather than a newly measured moving average. Current moving-average, turnover and short-interest observations are missing, so the evidence does not establish a rising support line, a squeeze or crowded positioning. Conviction remains low because the September 18 price record supplies no renewed momentum confirmation ahead of the next segment report.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Dividend payment. Genpact’s 2026-07-16 declaration scheduled payment of $0.1875 per share. This is the next dated company cash event in the supplied record; it does not resolve technology-revenue conversion.
• 2026-10-01 — Accenture fiscal results. Accenture’s 2026-09-15 announcement confirms this date, replacing the earlier September estimate. Its demand commentary provides a sector comparison; Genpact’s own segment results remain the company-specific test. Accenture announcement.
• ~2026-11-05, est. Genpact Q3 results. This later event is the thesis’s principal test. MarketBeat identifies the date as estimated; Genpact’s 2026-08-06 outlook calls for revenue of $1.369–1.382 billion and ATS growth of at least 25%. Estimated earnings calendar, filed outlook.

What Would Change Our Mind

The recovery structure fails on a weekly close below $32, the threshold published on 2026-09-05. Fundamental confirmation of failure would be Q3 ATS growth below 20% alongside an outright year-over-year Core Business Services revenue decline; these are research conditions, not management forecasts.

The positive case plays out if Q3 ATS growth reaches at least 25%, consolidated revenue reaches the guided $1.369 billion minimum, and management retains its full-year revenue-growth outlook of at least 7% before the weekly price condition fires. Those benchmarks come from the 2026-08-06 outlook. Meeting them would establish a quarter of revenue conversion; it would not establish a durable growth rate. Filed outlook.

Correlation Notes

This remains a single-company thesis: Genpact’s 2026-08-06 segment disclosure supplies the operating evidence. Accenture’s confirmed 2026-10-01 report is a comparison point for enterprise-services demand, not proof that the shares move together. Accenture event announcement.

No matched return series is available alongside the 2026-09-18 Genpact price record. The sample is too small to support a claim about correlation with software, Indian technology services or the broader market.